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Abstract
Objective
To determine whether publication of evidence on delays in time to treatment shortens time to treatment in
pediatric refractory convulsive status epilepticus (rSE), we compared time to treatment before (2011–2014)
and after (2015–2019) publication of evidence of delays in treatment of rSE in the Pediatric Status Epilepticus
Research Group (pSERG) as assessed by patient interviews and record review.
Methods
We performed a retrospective analysis of a prospectively collected dataset from June 2011 to September 2019
on pediatric patients (1 month–21 years of age) with rSE.
Results
We studied 328 patients (56% male) with median (25th–75th percentile [p25–p75]) age of 3.8 (1.3–9.4) years.
There were no diﬀerences in the median (p25–p75) time to ﬁrst benzodiazepine (BZD) (20 [5–52.5] vs 15
[5–38] minutes, p = 0.3919), time to ﬁrst non-BZD antiseizure medication (68 [34.5–163.5] vs 65 [33–142]
minutes, p = 0.7328), and time to ﬁrst continuous infusion (186 [124.2–571] vs 160 [89.5–495] minutes, p =
0.2236). Among 157 patients with out-of-hospital onset whose time to hospital arrival was available, the
proportion who received at least 1 BZD before hospital arrival increased after publication of evidence of delays
(41 of 81 [50.6%] vs 57 of 76 [75%], p = 0.0018), and the odds ratio (OR) was also increased in multivariable
logistic regression (OR 4.35 [95% conﬁdence interval 1.96–10.3], p = 0.0005).
Conclusion
Publication of evidence on delays in time to treatment was not associated with improvements in time to
treatment of rSE, although it was associated with an increase in the proportion of patients who received at least
1 BZD before hospital arrival.
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Glossary
ASM = antiseizure medication; BZD = benzodiazepine; CI = conﬁdence interval; HR = hazard ratio; ICU = intensive care unit;
OR = odds ratio; p25 = 25th percentile; p75 = 75th percentile; pSERG = Pediatric Status Epilepticus Research Group; RMST =
restricted mean survival time; rSE = refractory convulsive SE; SE = status epilepticus.

Status epilepticus (SE) is one of the most frequent neurologic
emergencies in children, with an incidence of 5 to 25 per
100,000.1–4 Longer SE episodes require more invasive and
resource-intensive medical care and are associated with higher
morbidity and mortality.5 Although long-term outcomes in
SE survivors depend largely on etiology,6,7 observational
studies showed that delayed treatment is independently associated with worse outcomes8–12 and increased mortality12
in the short term. Therefore, shortening SE duration through
timely and eﬀective treatment13–15 may improve short-term
outcomes.
The American Epilepsy Society guideline recommends initial
treatment with benzodiazepine (BZD) within 20 minutes,
treatment with non-BZD antiseizure medication (non-BZD
ASM) within 40 minutes, and treatment with continuous
infusions within 60 minutes,16 but a growing body of literature
identiﬁes marked delays from these benchmarks.17 Interdisciplinary quality improvement interventions have
shown that it is possible to improve time to treatment of
electrographic seizures in the intensive care unit (ICU)18 and
time to treatment of SE in the hospital.19,20 There are no data
on whether publication of evidence on delayed treatment in
SE has independently modiﬁed time to treatment.
We aimed to address this gap in knowledge by comparing
time to treatment before (2011–2014) and after (2015–2019)
publication of evidence of delays in time to treatment within
the Pediatric Status Epilepticus Research Group (pSERG).
Our hypothesis was that published evidence identifying a gap
in clinical practice (delayed time to treatment) would lead to
improved clinical practice (reduced times to treatment).

Methods
Standard protocol approvals, registrations,
and patient consents
This study was approved by the Institutional Review Board at
each institution. Written informed consent was obtained from
parents or guardians.
Study design
This was a retrospective analysis of prospectively collected
data from a multicenter observational study. pSERG is a
consortium of pediatric hospitals in the United States and
Canada that aims to improve the treatment and, eventually,
the prognosis of children with SE.21 pSERG, as an ongoing
study, has reported the initial patients in the cohort on different outcomes: on delays in time to treatment,22 use of
Neurology.org/N

continuous infusions,23 diﬀerences in time to treatment between patients with and without a prior diagnosis of epilepsy,24 factors associated with delays in time to treatment,25
and the association of treatment delays with unfavorable
outcomes.12
Patients
We studied patients with refractory convulsive SE (rSE). Inclusion criteria were (1) age from 1 month to 21 years; (2)
admission to a pSERG hospital between June, 1, 2011, and
September, 1, 2019; and (3) focal or generalized convulsive
seizures at onset that continued after administration of at least
2 ASMs, including at least 1 non-BZD ASM or the use of a
continuous infusion. Exclusion criteria were (1) nonconvulsive SE detected on EEG lacking convulsive seizures at
onset; (2) nonconvulsive SE with motor manifestations limited to infrequent myoclonic jerks; (3) no information on
time to administration of the ﬁrst BZD; (4) no information on
time to administration of the ﬁrst non-BZD ASM; and (5) no
information on basic demographic and clinical features such
as age, sex, race, time of SE onset, hospital onset, type of SE, or
duration of SE. In order not to violate the assumption of
independent observations in statistical tests, we included only
the ﬁrst rSE episode for patients who had >1 rSE episode
during the study period.
Variables
The main outcomes were time to the ﬁrst BZD, time to the
ﬁrst non-BZD ASM, and time to the ﬁrst continuous infusion
among patients who received any. Secondary outcomes were
the proportion of patients who received the ﬁrst class of each
medication (BZD, non-BZD ASM, and continuous infusion)
beyond recommended timelines and beyond clinically prespeciﬁed outlier times and, among patients with rSE onset out
of the hospital, the proportion of patients who received at
least 1 BZD before hospital arrival. The main intervention for
all analyses was publication of evidence from pSERG showing
delays in time to treatment.22 By the end of 2014, the ﬁrst
article with pSERG data showed that delays in time to treatment of rSE occurred at every step of the treatment pathway,
and all pSERG members became aware of delays in time to
treatment of rSE because they contributed to the article.22
Therefore, we divided time into the periods June 2011 to
December 2014 vs January 2015 to September 2019 as surrogates for preawareness and awareness of delays in time to
treatment. As more patients were collected, new pSERG
analyses in 2016 conﬁrmed the initial results and showed that
delays in time to treatment of rSE were common even in
patients with a prior diagnosis of epilepsy.24 Further, the
American Epilepsy Society evidence-based guideline
Neurology | Volume 95, Number 9 | September 1, 2020
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published in 2016 emphasized initial treatment with BZD
within 20 minutes, treatment with non-BZD ASM within 40
minutes, and treatment with continuous infusions within 60
minutes.16 Therefore, as a sensitivity analysis, we compared
times to treatment deﬁning alternative periods: 2011 to 2016
vs 2017 to 2019. We also evaluated the robustness of our
results with an additional sensitivity analysis considering only
the hospitals that were part of pSERG since the initial years.
We considered as potential confounders the type of SE
(continuous or intermittent), hospital onset, SE onset during
the day (8 AM–8 PM) or night (8 PM–8 AM), period in the
academic year (July–December vs January–June), white race,
etiology (structural vs other), history of epilepsy, prior episode of SE, age in years, and sex. The time to medication
administration was extracted from families and emergency
medical services for out-of-hospital SE onset and from provider documentation and medical records for SE treated in the
hospital. Data were collected with a standardized data acquisition tool and then entered into an electronic database
hosted by Cincinnati Children’s Hospital Medical Center.21
Statistical analysis and statistical software
Demographic and clinical characteristics were summarized
with descriptive statistics. Unless stated otherwise, continuous
variables were summarized as median (25th [p25] and 75th
[p75] percentile) and categorical variables were summarized
as number (percentage). Categorical variables were compared
with the Fisher exact test in univariate analysis and with logistic regression with multivariate analysis. We calculated the
absolute risk diﬀerence and the number needed to treat. We
compared time to treatment in univariate analysis with the
Peto and Peto modiﬁcation of the Gehan-Breslow-Wilcoxon
test and in multivariate analysis with a Cox proportional
hazards regression model. The Peto and Peto26 modiﬁcation
of the Gehan-Breslow-Wilcoxon test is a nonparametric
generalized maximum-likelihood estimate of the survival
function for interval-censored data that gives more weight to
early events and gives less weight to late events, likely outliers
in this context. We calculated the diﬀerences in time to
treatment between groups (before and after publication of
evidence of delays) with the diﬀerence of the restricted mean
survival time (RMST).27,28 The diﬀerence of the RMST is an
outcome measure that compares the time diﬀerence between
2 groups using the areas under the Kaplan-Meier curves up to
a clinically meaningful prespeciﬁed time.27,28 Considering a
clinically meaningful prespeciﬁed time of, e.g., 60 minutes for
the time to the ﬁrst BZD, a diﬀerence of RMST of, e.g., −3
minutes means that, within the ﬁrst 60 minutes, patients in the
group after publication of evidence received the ﬁrst BZD a
mean of 3 minutes earlier than patients in the group before
publication of evidence. For this study, we considered the
following clinically meaningful prespeciﬁed times: (1) 20, 40,
and 60 minutes for the ﬁrst BZD, which represent the times by
which the ﬁrst-line therapy should be completed, and 20 and
40 minutes after that threshold16; (2) 40, 60, and 120 minutes
for the ﬁrst non-BZD ASM, which represent the times by
which the second-line therapy should be completed, and 20
e1224
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and 80 minutes after that threshold16; and (3) 60, 120, and
240 minutes for the ﬁrst continuous infusion, which represent
the times by which the third-line therapy should be completed, and 60 and 180 minutes after that threshold.16 We
considered onset of rSE (in the hospital or out of the hospital)
as an eﬀect modiﬁer because time to treatment is likely to be
diﬀerent in these 2 environments. Thus, we stratiﬁed the
analyses by in-hospital or out-of-hospital rSE onset. We used a
conventional 2-sided α level of 0.05 for all tests because, even
if the expected eﬀect of publication of evidence of delays is to
reduce times to treatment, longer times to treatment might
have happened due to a secular eﬀect. We adjusted the main
results for multiple comparisons with the Benjamini and
Hochberg false discovery rate with a q value of 0.05.29 The
false discovery rate controls for the expected proportion of
false discoveries in order to control for multiple comparisons
across multiple tests.29 All statistical analyses were performed
with R (version 3.6.0; R Foundation for Statistical Computing, Vienna, Austria), a language and environment for statistical computing30 with RStudio,31 and the packages gdata,32
car,33 lubridate,34 gmodels,35 survival,36 and survRM2.37
Data availability
All statistical analyses and results are available in appendix e-1
(github.com/IvanSanchezFernandez/pSERGbeforeafter).
The original data are available on request.

Results
Demographic and clinical characteristics
We evaluated 328 patients (56% male) with a median
(p25–p75) age of 3.8 (1.3–9.4) years, 151 (46%) with an rSE
episode in the period 2011 to 2014 and 177 (54%) in the
period 2015 to 2019. SE started out of hospital in 222 (67.7%)
patients and in hospital in 106 (32.3%) patients. The median
(p25–p75) length of ICU stay was 4 (2–11) days, and 11
(3.4%) patients died during hospitalization (table 1).
Time to treatment
The median (p25–p75) time to the administration of the ﬁrst
BZD was 17 (5–45) minutes. There was no statistically signiﬁcant diﬀerence between the periods 2011 to 2014 and
2015 to 2019 (20 [5–52.5] vs 15 [5–38] minutes, p = 0.3919)
(ﬁgure 1A), and it was not signiﬁcant after adjustment for
potential confounders (confounders described in the Methods section) (hazard ratio [HR] 1.01 [95% conﬁdence interval (CI) 0.81–1.27], p = 0.9130) (table e-1, available in
GitHub at github.com/IvanSanchezFernandez/pSERGbeforeafter and in zenodo at zenodo.org/badge/latestdoi/
230197648). The median (p25–p75) time to the administration of the ﬁrst non-BZD ASM was 65.5 (33.8–150) minutes.
There was no diﬀerence between the periods 2011 to 2014
and 2015 to 2019 (68 [34.5–163.5] vs 65 [33–142] minutes, p
= 0.7328) (ﬁgure 1B), and it was not signiﬁcant after adjustment for potential confounders (HR 1.01 [95% CI
0.81–1.27], p = 0.9111) (table e-2, available in GitHub and
Neurology.org/N

Table 1 Demographic and clinical characteristics
2011–2014 (n = 151)

2015–2019 (n = 177)

Total (n = 328)

3.8 (1.2–8.9)

4.1 (1.3–9.6)

3.8 (1.3–9.4)

Male

80 (53)

103 (58.2)

183 (55.8)

Female

71 (47)

74 (41.8)

145 (44.2)

White

81 (53.6)

128 (72.3)

209 (63.7)

Black

38 (25.2)

27 (15.3)

65 (19.8)

Arabic

7 (4.6)

3 (1.7)

10 (3)

Asian

6 (4)

5 (2.8)

11 (3.4)

Native American

1 (0.7)

2 (1.1)

3 (0.9)

Unknown

18 (11.9)

12 (6.8)

30 (9.2)

Not Hispanic

111 (73.5)

136 (76.8)

247 (75.3)

Hispanic

26 (17.2)

25 (14.1)

51 (15.5)

14 (9.3)

16 (9)

30 (9.2)

Developmental delay/intellectual disability

76 (50.3)

91 (51.4)

167 (50.9)

Prior epilepsy

71 (47)

90 (50.8)

161 (49.1)

History of SE

26 (17.2)

36 (20.3)

62 (18.9)

History of cerebral palsy

13 (8.6)

18 (10.2)

31 (9.5)

No prior neurologic history

56 (37.1)

54 (30.5)

110 (33.5)

Unknown

47 (31.1)

65 (36.7)

112 (34.1)

Structural

44 (29.1)

39 (22)

83 (25.3)

Genetic

24 (15.9)

38 (21.5)

62 (18.9)

Metabolic

11 (7.3)

4 (2.3)

15 (4.6)

Other

25 (16.6)

31 (17.5)

56 (17.1)

Out of the hospital

105 (69.5)

117 (66.1)

222 (67.7)

In the hospital

46 (30.5)

60 (33.9)

106 (32.3)

Convulsive duration (n = 328), min

135 (60–275)

120 (60–286)

124.5 (60–281.5)

Length of ICU stay (n = 311), d

4.3 (2–11.9)

4 (1.7–11)

4 (2–11)

In-hospital mortality (n = 328), n (%)

5 (3.3)

6 (3.5)

11 (3.4)

Age, y
Sex, n (%)

Race, n (%)

Ethnicity, n (%)

Unknown
a

Medical history, n (%)

Etiology, n (%)

SE onset, n (%)

Abbreviations: ASM = antiseizure medication; BZD = benzodiazepine; SE = status epilepticus.
Continuous variables are summarized as median (25th–75th percentiles); categorical variables are summarized as number and percentage.
a
These conditions are not mutually exclusive; therefore, the percentages can sum to >100%.

zenodo). Among the 152 patients who received at least 1
continuous infusion, the median (p25–p75) time to the administration of the ﬁrst continuous infusion was 173.5
Neurology.org/N

(113.5–543.2) minutes. There was no statistically signiﬁcant
diﬀerence between the periods 2011 to 2014 and 2015 to
2019 (186 [124.2–571] vs 160 [89.5–495] minutes, p =
Neurology | Volume 95, Number 9 | September 1, 2020
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0.2236) (ﬁgure 1C), and it was not signiﬁcant after adjustment for potential confounders (HR 1.08 [95% CI
0.77–1.51], p = 0.6428) (table e-3, available in GitHub at and
zenodo).

Figure 1 Kaplan-Meier curves comparing the periods 2011
to 2014 and 2015 to 2019 on time to the administration of the first class of each medication (BZD,
non-BZD ASM, and CI)

Treatment within clinical recommendations
and outliers
Forty-three percent, 27%, and 19% of patients received their
ﬁrst BZD beyond 20, 40, and 60 minutes from seizure onset,
respectively. Seventy percent, 54%, and 29% of patients received their ﬁrst non-BZD ASM beyond 40, 60, and 120
minutes from seizure onset, respectively. Eighty-nine percent,
70%, and 39% of patients received their ﬁrst continuous infusion beyond 60, 120, and 240 minutes from seizure onset,
respectively. These proportions were similar between the
periods 2011 to 2014 and 2015 to 2019 (table 2).
Stratification by hospital onset
The proportion of patients receiving their ﬁrst BZD, ﬁrst nonBZD ASM, and ﬁrst continuous infusion beyond recommended time lines and beyond outliers was high in both outof-hospital onset and in-hospital onset SE and did not change
in the period 2015 to 2019 compared with the period 2011 to
2014 (table 2). Among the 157 patients with out-of-hospital
onset whose time to hospital arrival was available, 98 (62.4%)
received at least 1 BZD before hospital arrival. This proportion increased after publication of evidence of delays (41
of 81 [50.6%] vs 57 of 76 [75%], absolute risk reduction 0.24,
number needed to treat 4.1, p = 0.0018 [adjusted p =
0.0036]), and the odds ratio (OR) remained signiﬁcant in
multivariable logistic regression adjusting for potential confounders (confounders described in the Methods section)
(OR 4.35 [95% CI 1.96–10.3], p = 0.0005 [adjusted p =
0.0019]). Among the 85 patients with a history of epilepsy
whose rSE began out of hospital and whose information on
time to hospital arrival was available, 56 (65.9%) received at
least 1 BZD before hospital arrival. This proportion increased
after publication of evidence of delays (23 of 43 [53.5%] vs 33
of 42 [78.6%], absolute risk reduction 0.25, number needed to
treat 4.0, p = 0.0217 [adjusted p = 0.0220]), and the OR
remained signiﬁcant in multivariable logistic regression with
adjustment for potential confounders (OR 3.97 [95% CI
1.28–13.99], p = 0.0220 [adjusted p = 0.0220]). There were
no diﬀerences between the periods 2011 to 2014 and 2015 to
2019 in time to the ﬁrst BZD, time to the ﬁrst non-BZD ASM,
and time to the ﬁrst continuous infusion for out-of-hospital or
in-hospital onset (table 3, ﬁgure 2, and appendix e-1, github.
com/IvanSanchezFernandez/pSERGbeforeafter).
Sensitivity analyses
There was no diﬀerence in time to treatment between the
periods (1) when considering the alternative periods 2011 to
2016 vs 2017 to 2019 rather than 2011 to 2014 vs 2015 to
2019; (2) when considering only hospitals that had patients
enrolled since the initial years of pSERG, using the original
periods 2011 to 2014 vs 2015 to 2019; and (3) when considering only hospitals that had patients enrolled since the
e1226
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Time scales are truncated for different medications (time to first benzodiazepine [BZD] truncated at 60 minutes, time to first non-BZD antiseizure
medication [ASM] truncated at 120 minutes, and time to first continuous
infusion [CI] truncated at 500 minutes). (A) Cumulative probability of having
received the first BZD. Time axis is truncated at 60 minutes. (B) Cumulative
probability of having received the first non-BZD ASM. Time axis is truncated
at 120 minutes. (C) Cumulative probability of having received the first CI
(among those patients who received a CI). Time axis is truncated at 500
minutes.

initial years of pSERG, using the alternative periods 2011 to
2016 vs 2017 to 2019. These sensitivity analyses also conﬁrmed that, among patients with out-of-hospital onset rSE,
Neurology.org/N

Table 2 Proportion of patients receiving each class of medication beyond clinically relevant times
Global
proportion,
n/N (%)

2011–2014,
n/N (%)

2015–2019,
n/N (%)

p Value (Fisher
exact test)

RMST difference (95%
confidence interval), min

p Value (RMST
difference)

First BZD >20 min

141/328 (43)

69/151 (45.7)

72/177 (40.7)

0.3728

−0.3 (−1.9 to 1.2)

0.665

First BZD >40 min

90/328 (27.4)

47/151 (31.1)

43/177 (24.3)

0.1743

−1.7 (−4.9 to 1.5)

0.286

First BZD >60 min

62/328 (18.9)

34/151 (22.5)

28/177 (15.8)

0.1568

−2.9 (−7.5 to 1.7)

0.214

First non-BZD
ASM >40 min

231/328 (70.4)

106/151
(70.2)

125/177
(70.6)

1

−0.8 (−2.6 to 1.1)

0.421

First non-BZD
ASM >60 min

178/328 (54.3)

81/151 (53.6)

97/177 (54.8)

0.9115

−0.6 (−4 to 2.8)

0.722

First non-BZD
ASM >120 min

95/328 (29)

46/151 (30.5)

49/177 (27.7)

0.6258

−2.1 (−10.1 to 5.9)

0.607

First CI >60 min

135/152 (88.8)

62/68 (91.2)

73/84 (86.9)

0.4493

0.6 (−2.4 to 3.6)

0.698

First CI >120 min

107/152 (70.4)

52/68 (76.5)

55/84 (65.5)

0.1562

−5.4 (−14.2 to 3.3)

0.222

First CI >240 min

59/152 (38.8)

29/68 (42.6)

30/84 (35.7)

0.4067

−12.7 (−35.8 to 10.4)

0.282

First BZD >20 min

107/222 (48.2)

55/105 (52.4)

52/117 (44.4)

0.2821

−0.6 (−2.3 to 1.2)

0.537

First BZD >40 min

71/222 (32)

37/105 (35.2)

34/117 (29.1)

0.3874

−1.9 (−5.8 to 2)

0.332

First BZD >60 min

47/222 (21.2)

26/105 (24.8)

21/117 (17.9)

0.2505

−2.8 (−8.6 to 3)

0.338

First non-BZD
ASM >40 min

178/222 (80.2)

82/105 (78.1)

96/117 (82.1)

0.5025

−0.3 (−2.1 to 1.6)

0.797

First non-BZD
ASM >60 min

142/222 (64)

65/105 (61.9)

77/117 (65.8)

0.5773

0.9 (−2.7 to 4.5)

0.623

First non-BZD
ASM >120 min

78/222 (35.1)

39/105 (37.1)

39/117 (33.3)

0.5757

0.3 (−9.3 to 9.8)

0.956

First CI >60 min

90/101 (89.1)

42/45 (93.3)

48/56 (85.7)

0.3373

−0.4 (−2.7 to 1.9)

0.733

First CI >120 min

73/101 (72.3)

35/45 (77.8)

38/56 (67.9)

0.3714

−5.4 (−14.8 to 4.1)

0.263

First CI >240 min

41/101 (40.6)

19/45 (42.2)

22/56 (39.3

0.8395

−6 (−32.8 to 20.8)

0.659

First BZD >20 min

34/106 (32.1)

14/46 (30.4)

20/60 (33.3)

0.835

−0.1 (−2.9 to 2.7)

0.953

First BZD >40 min

19/106 (17.9)

10/46 (21.7)

9/60 (15)

0.4467

−1.5 (−6.8 to 3.8)

0.574

First BZD >60 min

15/106 (14.2)

8/46 (17.4)

7/60 (11.7)

0.4158

−3.2 (−10.6 to 4.2)

0.400

First non-BZD
ASM >40 min

53/106 (50)

24/46 (52.2)

29/60 (48.3)

0.8448

−1.6 (−5.5 to 2.2)

0.410

First non-BZD
ASM >60 min

36/106 (34)

16/46 (34.8)

20/60 (33.3)

1

−3.6 (−10.3 to 3.1)

0.292

First non-BZD
ASM >120 min

17/106 (16)

7/46 (15.2)

10/60 (16.7)

1

−6.3 (−20.1 to 7.4)

0.365

First CI >60 min

45/51 (88.2)

20/23 (87)

25/28 (89.3)

1

2.9 (−3.9 to 9.7)

0.410

First CI >120 min

34/51 (66.7)

17/23 (73.9)

17/28 (60.7)

0.381

−2.8 (−19.3 to 13.7)

0.739

First CI >240 min

18/51 (35.3)

10/23 (43.5)

8/28 (28.6)

0.3784

−23.4 (−64.1 to 17.4)

0.260

Total population

Out of hospital
onset

In hospital onset

Abbreviations: ASM = antiseizure medication; BZD = benzodiazepine; CI = continuous infusion; RMST = restricted mean survival time.
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the proportion of patients who received at least 1 BZD before
hospital arrival increased after publication of evidence on
delays (table e-4 and appendix e-1, available in GitHub at
github.com/IvanSanchezFernandez/pSERGbeforeafter and
in zenodo at zenodo.org/badge/latestdoi/230197648 and
ivansanchezfernandez.github.io/pSERGbeforeafter_
Filee1/).

Discussion
This study demonstrates that, in major pediatric hospitals,
publication of evidence showing a gap in clinical practice
(delayed treatment in rSE) was not associated with an improvement in clinical practice (sustained reduction in time to
treatment for any of the management steps). It was associated,
however, with a clinically meaningful improvement: the increase in the proportion of patients with out-of-hospital rSE
onset who received at least 1 BZD before hospital arrival. This
improvement is probably related to better education of
caregivers about seizure action plans, a step that is largely
dependent on epileptologists and pediatric neurologists. In
turn, the failure of improving time to treatment probably
reﬂects the lack of an implementation policy that includes
dissemination of evidence among all stakeholders, modiﬁcation of standardized treatment plans to emphasize time to
treatment, and implementation by multidisciplinary teams.
pSERG is a large multicenter study that includes major pediatric hospitals in the United States and Canada. Evaluation
of time to treatment was an open research question within
pSERG in the years 2011 to 2014. Existing literature at the
time suggested that treatment delay was common in both
children and adults with SE, but evidence was sparse and
limited to the ﬁrst treatment steps.38 A retrospective study in

625 adults and 264 children with SE in the 1989 to 1994
period in Virginia showed that the ﬁrst ASM (BZD or nonBZD ASM) was given within 30 minutes of seizure onset in
only 42% of cases.39 Similarly, a study of 542 episodes of
pediatric SE in the period 2000 to 2004 in Australia and New
Zealand showed that the median (p25–p75) time from hospital
arrival to administration of a non-BZD ASM was 24 (15–36)
minutes.40 In a study of 263 clinical SE episodes in 225 adult
patients in the 2008 to 2011 period in Switzerland showed
that initial treatment was delayed for >1 hour in 139 (62%) of
patients, including 54 patients with generalized convulsive
SE.41 By the end of 2014, pSERG had collected data that
demonstrated delays at every treatment step, and all pSERG
members were aware of these delays.22 Therefore, we compared the periods 2011 to 2014 and 2015 to 2019. Our results
remained robust to the alternative comparison of periods
2011 to 2016 and 2017 to 2019 when the evidence for delays
was even stronger.24 Our results were also robust when
considering only the hospitals that formed pSERG initially.
Our main results remained robust to these sensitivity analyses
and together show no major improvements in time to treatment within pSERG after publication of evidence of delays in
time to treatment.
Unfortunately, the publication of evidence, even in major
scientiﬁc journals, is not necessarily suﬃcient to modify
clinical practice.42,43 The major stakeholders to reduce time to
treatment in SE are the primary caregivers, emergency medical services, emergency department clinicians, general pediatrics and internal medicine clinicians, and adult and child
neurologists and epileptologists. Most epileptologists and
adult and child neurologists are aware of the importance of
early treatment but typically are not the initial responders to
prolonged seizures. SE treatment is often initiated by primary
caregivers, emergency medical services personnel, and

Table 3 Comparison of time to treatment before and after awareness of marked delays in treatment administration for SE
Univariate
analysis

Multivariate analysis, HR (95% confidence
interval)

20 (7–50)

0.2606

1.06 (0.81–1.39), p = 0.6829

82 (45–190)

80 (55–153)

0.9441

1.02 (0.78–1.35), p = 0.877

180
(137–660)

166
(86.5–586.5)

0.3165

1.27 (0.82–1.97), p = 0.279

46

60

Time to the first BZD (n = 106), min

8 (4.3–25.8)

9.5 (5–24)

0.6778

1 (0.67–1.52), p = 0.974

Time to the first non-BZD ASM (n = 106), min

44.5
(20.3–86.8)

36 (23–79.8)

0.8215

1.12 (0.74–1.7), p = 0.5938

Time to the first continuous infusion (n =
51), min

210
(121–462)

147.5
(90.8–420)

0.4022

1.14 (0.6–2.16), p = 0.684

2011–2014

2015–2019

105

117

Time to the first BZD (n = 222), min

25 (7–60)

Time to the first non-BZD ASM (n = 222), min
Time to the first continuous infusion (n =
101), min

SE onset out of the hospital (n = 222), n

SE onset in the hospital (n = 106), n

Abbreviations: ASM = antiseizure medication; BZD = benzodiazepine; HR = hazard ratio; SE = status epilepticus.
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Figure 2 Kaplan-Meier curves comparing the periods 2011 to 2014 and 2015 to 2019 on time to the administration of the
first class of each medication (BZD, non-BZD ASM, and CI) stratified by onset out of the hospital (left) or in the
hospital (right)

Time scales are truncated for different medications (time to first benzodiazepine [BZD] truncated at 60 minutes, time to first non-BZD antiseizure medication
[ASM] truncated at 120 minutes, and time to first continuous infusion [CI] truncated at 500 minutes). (A) Cumulative probability of having received the first
BZD in patients with refractory convulsive status epilepticus (rSE) onset out of the hospital. Time axis is truncated at 60 minutes. (B) Cumulative probability of
having received the first non-BZD ASM in patients with rSE onset out of the hospital. Time axis is truncated at 120 minutes. (C) Cumulative probability of having
received the first CI (among those patients who received a CI) in patients with rSE onset out of the hospital. Time axis is truncated at 500 minutes. (D)
Cumulative probability of having received the first BZD in patients with rSE onset in the hospital. Time axis is truncated at 60 minutes. (E) Cumulative
probability of having received the first non-BZD ASM in patients with rSE onset in the hospital. Time axis is truncated at 120 minutes. (F) Cumulative probability
of having received the first CI (among those patients who received a CI) in patients with rSE onset in the hospital. Time axis is truncated at 500 minutes.

emergency department physicians, typically in community
hospitals, who may not receive as much training in the importance of time to treatment of SE as in large academic
centers. Neurologists and epileptologists need to continue to
ensure a timely treatment when directly caring for a patient
with active SE, but they may also improve time to treatment
by acting as knowledge brokers who transfer the importance
of a timely treatment to all initial responders. Educating
Neurology.org/N

primary caregivers about individualized seizure action plans
and simulating likely SE treatment scenarios to make primary
caregivers comfortable administering rescue medications may
improve the timeliness and eﬃcacy of the treatment of SE.
This transfer of knowledge can occur during routine epilepsy
clinic visits; local, regional, and national education; and
meetings, directly or through dedicated nursing teams. Support of these education eﬀorts by hospital administrators and
Neurology | Volume 95, Number 9 | September 1, 2020
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leadership and recognition by payers are crucial, as are education of and acceptance by patients and caregivers, because
implementation ultimately remains a shared responsibility.
We observed a clinical relevant improvement in the proportion of patients who received at least 1 BZD before hospital arrival, although this may reﬂect the growing body of
literature suggesting room for improvement in the proportion
of caregivers trained in administration of rescue medications
for prolonged seizures44 and in the proportion of patients not
treated before hospital arrival.22 In either case, if the observed
improvement is the result of epileptologists and pediatric
neurologists better educating families on seizure action plans,
it provides a model to educate all the caregivers in the SE
treatment chain. Another potential source of delays is that
some systemic factors are beyond the control of clinicians. For
example, emergency medical services may not be allowed to
administer BZD and non-BZD ASM in the out-of-hospital
setting, and once in the hospital, the period from ASM order
to ASM arrival to the bedside may be long and beyond clinicians’ control, likely requiring further education and dissemination eﬀorts, as well as systematic improvements and
policy changes. Despite isolated quality improvement projects, there have not been general policies within pSERG
hospitals to formally disseminate information on delays in
time to treatment of SE to personnel working in emergency
medical services, emergency departments, general pediatrics,
pharmacy, nursing, or the ICU. If knowledge is not widely
disseminated, improvement based on that knowledge is unlikely to be as large as it could be. Although numbers are not
large enough to study each center individually, we did not ﬁnd
any center with improved times after publication of evidence.
The time lag from the discovery of a new research ﬁnding to
its implementation into medical practice varies widely,
depending on the research ﬁnding, but typically takes several
years.43 Slow tendencies toward improvement may not have
been captured in this study, which spans less than a decade. In
addition, a tendency for improvement may have been compensated by patients with better treatments not progressing
into rSE and therefore not meeting our inclusion and exclusion criteria. Although possible, this is unlikely because we
have not seen improvement even in the time to the ﬁrst BZD.
There have been no national or consortium-related formal
mechanisms to translate research knowledge into policy
changes, and work is in progress to secure funding for further
implementation eﬀorts and to amend this crucial aspect.
Therefore, the transfer of knowledge between pSERG child
neurologists and other stakeholders in hospitals, referring
emergency department networks, and the policy changes
implemented in the pSERG hospitals have been variable, in
part also due to lack of overarching guideline and government
input, delay of implementation of clinical ﬁndings into health
care policies on a regional and national level, and further
delays in implementation and monitoring of updated policies.
Formal quality improvement projects can improve the eﬃciency and timeliness of treatment administration. A quality
improvement study on the timely detection and treatment of
e1230
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electrographic seizures in the ICU reduced the time from
seizure onset to medication administration by half and improved the percentage of seizure termination after the ﬁrst
ASM from 67% to 27%.18 Its multidisciplinary approach involving all stakeholders and streamlining protocols may be a
model to follow in convulsive SE.18 A quality improvement
project on the treatment of convulsive SE reduced the median
time to the second-line ASM by half.19 In a pSERG tertiary
care pediatric hospital, implementation of process improvements developed through quality improvement and statistical
process control methodology doubled the proportion of patients receiving a ﬁrst BZD within 10 minutes, thereby
resulting in decreases in morbidity, transfer to the ICU, and
costs.20 This study did not only show that multidisciplinary
quality improvement projects may reduce time to treatment,
but it also showed the magnitude of the downstream consequences: need for ICU transfer was reduced from 39% to 9%
of SE cases, reducing hospital charges by $2.1 million in a
single hospital. These data highlight the need for pSERG-wide
multidisciplinary, systems-focused approaches that include
streamlining of communication; formal dissemination of the
research ﬁndings on the importance of a timely treatment to
all stakeholders; policy changes to streamline drug delivery; a
standardized education of caregivers, emergency medical
services, and emergency room personnel about speciﬁc steps
to treat SE in a timely manner to avoid unnecessary delays and
redundant interventions (table 4); and ultimately ﬁnancial
motivation for payers and health care systems to implement
care improvements. Publication of evidence is a ﬁrst step that
may or may not improve practice.42 Lack of improvement in
clinical practice after publication of evidence on a gap in
practice may reﬂect the lack of policy changes to implement
this knowledge. Epileptologists and pediatric neurologists
who participated in the pSERG research studies became
aware of the results. This may have contributed to the improvement in seizure action plans. Yet, there have been no
pSERG-wide, regional, or national policy changes to formally
disseminate knowledge on delays in time to treatment of SE
to all stakeholders, work to emphasize timeliness in treatment
protocols, and audit change. Quality improvement methodology does not merely rely on passive diﬀusion of evidence
but adopts the scientiﬁc method to, through multiple cycles,
identify and implement the strategies that lead to the desired
goal of improved practice.45,46
Comparing times to treatment between periods within individual centers was not feasible with the current numbers,
although descriptive data showed no improvement in any
center. Our sample included patients with rSE and is not
necessarily representative of all children with SE. Although
pSERG collects cases with nonrefractory SE, this collection
began on October 2014 and, therefore, we cannot compare
time to treatment before and after publication of evidence of
delays in this population. Selection bias resulting from having
studied only rSE may limit the generalizability of results, but it
would not be expected that time to treatment would have
improved only in nonrefractory SE. Members of pSERG are
Neurology.org/N

Table 4 Steps to improve time to treatment
Potential barriers to timely treatment

Proposed actions

Limited awareness of the importance of a timely and well-dosed
treatment of SE to improve short-term outcomes

Neurologists and epileptologists act as knowledge brokers disseminating
research findings to all involved stakeholders.

Delayed recognition of seizure by caregivers and teachers
Delayed recognition of seizures during sleep

Increase general awareness through education of general public and
targeted groups (e.g., teachers, day care providers, etc).
Provide monitoring devices.

Limited access to rescue medications and proper seizure action plans for
patients with epilepsy

Improve seizure action plan education.
Develop dedicated nursing teams that simulate likely seizure action plan
scenarios for each family in each epilepsy clinic visit.

Low proportion of patients with SE treatment by EMS

Modify regulations to allow EMS to administer appropriate medications in
the appropriate circumstances.
Educate policy makers and EMS about the importance of a timely
treatment.

Delayed, reduced, or redundant ASM treatment in community
emergency departments related to low volume of pediatric patients

Increase collaborations with academic children’s hospitals and
community hospitals referring patients.
Provide training modules with emergency department professionals.
Educate primary caregivers, EMS, and emergency department personnel
about the importance of an appropriate dosage of rescue medications.

Delayed, reduced, or redundant ASM treatment in academic center
emergency departments related to provider experience or logistical
barriers

Create pathways standardizing care for SE.
Train and retrain staff on current recommendations.
Provide training modules with emergency department professionals.
Develop multidisciplinary teams with the goal of identifying and modifying
barriers to ASM ordering, acquisition, and administration.
Re-engineer systems to streamline access to rescue medication in the
acute treatment of SE.

Delayed or reduced ASM treatment in the ICU

Create pathways standardizing care for SE.
Provide training modules with ICU professionals.
Establish EEG monitoring expectations.
Establish communication flow from initial point of epileptologist to
endpoint of bedside caregivers.

Abbreviations: ASM = antiseizure medication; EMS = emergency medical services; ICU = intensive care unit; SE = status epilepticus.

fully aware of marked delays in time to treatment of SE because
they all participated in prior pSERG studies and literature review; however, the degree to which physicians in other specialties (e.g., emergency medicine, general pediatrics, critical
care medicine) are aware of the delayed time to SE treatment
and the association between treatment times and outcomes is
unknown.8–12 We also are not sure to what extent delayed
treatment depends on clinicians prescribing it late vs clinicians
prescribing it soon but medication administration being
delayed by systemic factors beyond clinician control that hinder
expeditious administration of medication. Times were assessed
based on caregiver and emergency medical services information
for out-of-hospital onset and from health care personnel information and hospital records once in the hospital. Information was cross-referenced with caregivers, emergency
medical services, nurses, and medication administration records when available to minimize potential information and
recall bias. Other studies on the treatment of SE active during
this period, such as the SAGE 547 trial for super-refractory SE47
and the established SE treatment trial,48 did not focus on time
to treatment and are unlikely to have confounded the perception of treatment delays.
In a large multicenter consortium of leading pediatric hospitals, publication of evidence on delays in treatment of rSE
Neurology.org/N

among epileptologists and child neurologists did not translate
into improvements in time to treatment, although it was associated with an increase in the proportion of patients who
received at least 1 BZD before hospital arrival. Because little
change has occurred, pSERG will implement interventions to
increase public awareness and multidisciplinary care plans to
improve time to treatment.
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